IO Biotech 将来の成長

Future 基準チェック /06

IO Biotech利益と収益がそれぞれ年間4.5%と77.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-217.7% 25.1%なると予測されています。

主要情報

4.5%

収益成長率

25.1%

EPS成長率

Biotechs 収益成長	28.5%
収益成長率	77.8%
将来の株主資本利益率	-217.7%
アナリストカバレッジ	Low
最終更新日	13 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqGS:IOBT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	23	-127	-102	N/A	4
12/31/2025	N/A	-113	-96	N/A	4
12/31/2024	N/A	-90	-80	N/A	4
9/30/2024	N/A	-90	-86	-86	N/A
6/30/2024	N/A	-88	-81	-81	N/A
3/31/2024	N/A	-88	-82	-82	N/A
12/31/2023	N/A	-86	-72	-72	N/A
9/30/2023	N/A	-80	-62	-61	N/A
6/30/2023	N/A	-74	-59	-59	N/A
3/31/2023	N/A	-71	-54	-54	N/A
12/31/2022	N/A	-71	-60	-60	N/A
9/30/2022	N/A	-74	-67	-66	N/A
6/30/2022	N/A	-65	-62	-61	N/A
3/31/2022	N/A	-87	-58	-58	N/A
12/31/2021	N/A	-75	-41	-41	N/A
9/30/2021	N/A	-56	-25	-24	N/A
6/30/2021	N/A	-54	-18	-18	N/A
3/31/2021	N/A	-17	-11	-11	N/A
12/31/2020	N/A	-15	-10	-10	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IOBT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IOBT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IOBT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IOBT来年は収益がないと予測されています。

高い収益成長: IOBT来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IOBT 3 年以内に赤字になると予測されています。

IO Biotech 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 13% to US$8.50

Price target decreased by 15% to US$9.67

Price target decreased to US$17.50

Recent updates

IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck Cancer

Price target decreased by 13% to US$8.50

IO Biotech, Inc. Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

New major risk - Financial position

New minor risk - Share price stability

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors

IO Biotech, Inc., Annual General Meeting, Jun 06, 2024

New minor risk - Market cap size

IO Biotech Announces Marjan Shamsaei as Senior Vice President

IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103

IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer

IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting

New major risk - Revenue and earnings growth

New minor risk - Market cap size

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

High number of new directors

IO Biotech Appoints Helen Collins, Md, to Its Board of Directors

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Price target decreased by 15% to US$9.67

IO Biotech, Inc. Appoints Heidi Hunter to Its Board of Directors

IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investors

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center

IO Biotech, Inc. Announces Executive Changes

New minor risk - Share price stability

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech, Inc. Appoints Christine Richter as Senior Vice President, Commercial and Program Lead

Chief Financial Officer recently bought US$58k worth of stock

IO Biotech Appoints Devin Smith as General Counsel and Chief Compliance Officer

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Price target decreased to US$17.50

IO Biotech, Inc. Announces Appointment of Amy Sullivan as Chief Financial Officer

IO Biotech names new CFO

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech GAAP EPS of -$0.64

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

IO Biotech, Inc. Announces Executive Changes

High number of new directors

High number of new directors

IO Biotech, Inc. Announces its Two Directors Not Stand for Re-Election

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

IO Biotech, Inc. Announces Appointment of David V. Smith to Board of Directors

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘